PRF Technologies (PRFX) Cash & Current Investments (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Cash & Current Investments of $4.1 million for Q4 2025, down 2.82% year-on-year from $4.3 million in Q4 2024, and up 18.52% on a QoQ basis from $3.5 million in Q2 2025.
PRF Technologies (PRFX) Cash & Current Investments (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Cash & Current Investments for 7 consecutive years, with $4.1 million the latest figure, recorded in Q4 2025.
- Quarterly Cash & Current Investments fell 2.82% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 2.82% YoY) and the FY2025 annual result came in at $4.1 million, down 2.82% from the prior year.
- Cash & Current Investments improved to $4.1 million in Q4 2025 per PRFX's latest filing, from $3.5 million in the prior quarter.
- Over the last five years, Cash & Current Investments for PRFX reached as high as $19.4 million in Q1 2021 and fell as low as $2.8 million in Q2 2024.
- A 5-year average of $10.3 million and a median of $8.2 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2021 — Cash & Current Investments surged 3137.09% — and 2023, when it slumped 55.57%.
- Year by year, Cash & Current Investments stood at $16.5 million in 2021, then tumbled by 38.44% to $10.2 million in 2022, then slipped by 21.17% to $8.0 million in 2023, then tumbled by 46.91% to $4.3 million in 2024, then decreased by 2.82% to $4.1 million in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $4.1 million, $3.5 million, and $4.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | PRF Technologies | 706,290.59 | -3.43 Mn | - | 4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.14 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Sep 30, 2023 | 7.56 Mn |
| Jun 30, 2023 | 6.16 Mn |
| Mar 31, 2023 | 8.15 Mn |
| Dec 31, 2022 | 10.18 Mn |
| Sep 30, 2022 | 12.98 Mn |
| Jun 30, 2022 | 13.87 Mn |
| Mar 31, 2022 | 16.57 Mn |
| Dec 31, 2021 | 16.54 Mn |
| Sep 30, 2021 | 18.34 Mn |
| Jun 30, 2021 | 17.80 Mn |
| Mar 31, 2021 | 19.44 Mn |
| Dec 31, 2020 | 15.68 Mn |
| Sep 30, 2020 | 17.72 Mn |
| Jun 30, 2020 | 550,000.00 |